SCHEMBL8532902

SCHEMBL8532902

CC(C)(C)c1cc(C=C2SC(=S)N(N)C2=O)ccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 1/20 0.58
HSD17B3 P37058 4/20 0.52
HSPD1 P10809 1/20 0.48
HSPE1 P61604 1/20 0.48
PDE4B Q07343 2/20 0.47
CFTR P13569 2/20 0.46
SLC2A1 P11166 2/20 0.46
MEN1 O00255 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
HSP90AA1 P07900 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
KDM4E B2RXH2 1/20 0.46
JAK2 O60674 1/20 0.46
NSD2 O96028 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8532901 1.00 NAT1 (0.58) NAT1HSD17B3HSPD1HSPE1PDE4B
SCHEMBL8710472 0.86 HSD17B3 (0.70) NAT1HSD17B3HSPD1HSPE1MEN1
SCHEMBL8710470 0.86 HSD17B3 (0.70) NAT1HSD17B3HSPD1HSPE1MEN1
SCHEMBL7702501 0.86 NAT1 (0.70) NAT1MEN1GAAKMT2AALDH1A1
SCHEMBL7702499 0.86 NAT1 (0.70) NAT1MEN1GAAKMT2AALDH1A1
SCHEMBL2532230 0.84 HSPD1 (0.64) NAT1HSD17B3HSPD1HSPE1PDE4B
SCHEMBL14788079 0.84 HSPD1 (0.64) NAT1HSD17B3HSPD1HSPE1PDE4B
SCHEMBL2532232 0.84 HSPD1 (0.64) NAT1HSD17B3HSPD1HSPE1PDE4B
SCHEMBL6884835 0.75 MEN1 (0.51) MEN1GAAKMT2APOLBKDM4E
SCHEMBL6884833 0.75 MEN1 (0.51) MEN1GAAKMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed